Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 596 of 6351
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD)…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to deepen remissions in Hard-to-Treat myeloma
Disease control Recruiting nowThe primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific …
Phase 2 • Sponsor: Duke University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug could replace standard infusions for nerve disorder
Disease control Recruiting nowThe main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 mo…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Phase 2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
A finger-prick test that could outpace measles outbreaks
Diagnosis Stopped earlyThe goal of this study is to measure the accuracy of a new measles rapid test when used in clinical health centres in several regions of Senegal. The rapid test will be used to test patients for measles who attend the participating health centres with signs and symptoms suggestiv…
Sponsor: Institut Pasteur de Dakar • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail shows promise for cervical cancer before surgery
Disease control Recruiting nowLocally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:30 UTC
-
Can a stronger radiation blast tame pancreatic cancer?
Disease control Recruiting nowThis phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care options include additional chemotherapy, …
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Double-Barreled antibody attack aims to wipe out hidden myeloma cells
Disease control Recruiting nowMultiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis than those with MRD negative disease. Bispecific …
Phase 2 • Sponsor: Noffar Bar • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a common antibiotic slash deaths from brain TB?
Disease control Recruiting nowAlthough tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary hospital centers. At present, the SOC for the management …
Phase 2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a Botox-Like shot stop migraines before they start?
Prevention Recruiting nowIn this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details includ…
Phase 3 • Sponsor: Merz Therapeutics GmbH • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a stronger flu shot better protect seniors?
Vaccine CompletedThis is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.
Phase 1 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
-
Triple-Drug cocktail takes on recurrent gynecologic cancers
Disease control Recruiting nowThis Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic cervical cancer and endometrial cancer.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough lymphoma: experimental drug ICP-248 targets relapsed mantle cell cancer
Disease control Recruiting nowThis is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
Phase 2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Needles vs. nausea: electroacupuncture trial aims to calm chemo side effects
Symptom relief Recruiting nowThis study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects an…
Phase 3 • Sponsor: Jiuda Zhao • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Can a Patient's own immune cells be engineered to fight a rare sarcoma?
Cure OngoingA single patient study to determine whether GCAR1 is safe and effective for refractory, progressive metastatic alveolar soft part sarcoma (ASPS).
Early phase 1 • Sponsor: University of Calgary • Aim: Cure
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows promise against tough skin cancer
Disease control Recruiting nowThis is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
AI crystal ball for hospital wards: can software forecast oxygen drops 24 hours early?
Diagnosis CompletedThe purpose of this retrospective study is to evaluate the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypoxia within 24 hours using vital-sign data from adult general ward inpatients. …
Sponsor: Huinno AIM • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Could less radiation be better? new trial aims to reduce side effects for advanced nose cancer patients
Disease control Recruiting nowIn order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment …
Phase 3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy combo shows promise against tough colorectal cancer
Disease control OngoingImmunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer. According to the existing theory, the use of Iparomlimab and Tuvonralimab may be the best solution. In this study, the investigators will pe…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a $4 heart pill beat a cancer? new trial tests propranolol for kaposi sarcoma
Disease control Recruiting nowKaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the m…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC